Display options
Cite
Manji F, Wierstra B, Posadas J. Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue. Case Rep Crit Care. 2017;2017:8747326doi: 10.1155/2017/8747326.
Manji, F., Wierstra, B., & Posadas, J. (2017). Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue. Case reports in critical care, 20178747326. https://doi.org/10.1155/2017/8747326
Manji, Farheen, et al. "Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue." Case reports in critical care vol. 2017 (2017): 8747326. doi: https://doi.org/10.1155/2017/8747326
Manji F, Wierstra B, Posadas J. Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue. Case Rep Crit Care. 2017;2017:8747326. doi: 10.1155/2017/8747326. Epub 2017 Oct 02. PMID: 29098094; PMCID: PMC5642875.
Copy Download .nbib Format: NLM
Share it on

Case Rep Crit Care. 2017;2017:8747326. doi: 10.1155/2017/8747326. Epub 2017 Oct 02.

Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue.

Case reports in critical care

Farheen Manji, Benjamin Wierstra, Juan Posadas

Affiliations

  1. University of Calgary and Alberta Health Services, Calgary, AB, Canada.
  2. Department of Medicine, University of Calgary, Calgary, AB, Canada.
  3. Department of Critical Care, University of Calgary, Calgary, AB, Canada.

PMID: 29098094 PMCID: PMC5642875 DOI: 10.1155/2017/8747326

Abstract

Methylene blue is a phenothiazine-related heterocyclic aromatic molecule presently used in the treatment of methemoglobinemia. Recently, it has been implicated in the treatment of severe refractory vasoplegic shock caused by anaphylaxis, sepsis, or postcardiopulmonary bypass. We present a case of a 27-year-old male with profound vasoplegic shock of unknown etiology which was refractory to vasopressors who responded within hours to a single dose of methylene blue. Additionally, we review the evidence of methylene blue's role in the treatment of shock. This case illustrates a diagnostic approach and treatment options in the setting of undifferentiated vasodilatory shock and outlines a new and emerging role for methylene blue in this clinical setting.

References

  1. N Engl J Med. 2001 Aug 23;345(8):588-95 - PubMed
  2. J Med Toxicol. 2013 Sep;9(3):242-9 - PubMed
  3. Pharmacotherapy. 2010 Jul;30(7):702-15 - PubMed
  4. Ann Thorac Surg. 2004 Feb;77(2):496-9 - PubMed
  5. Clin Toxicol (Phila). 2016 Aug;54(7):547-55 - PubMed
  6. Anesth Analg. 2016 Jan;122(1):194-201 - PubMed

Publication Types